FDA-&-EMA-New-Drug Approvals(Mid-2020 Recap)-insert

Find Clinical Drug Pipeline Developments & Deals by PACT Pharma


All Data

Filters Filter refresh
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NeoTCR-T cell

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Vida Ventures

            Deal Size: $75.0 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing January 10, 2020


            PACT Pharma Series C proceeds wili expand the scope of its clinical plan to investigate NeoTCR-T cell products targeting multiple neoantigens for a spectrum of solid tumor types.